Vascular calcification is dependent on plasma levels of pyrophosphate

Kidney International

Volumn 85, Issue 6, 2014, Pages 1351-1356

  Lomashvili, Koba A ^a   Narisawa, Sonoko ^b   Millán, Jose L ^b   O'Neill, W Charles ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BURNHAM INSTITUTE   (United States)

Author keywords

alkaline phosphatase; ectonucleotide pyrophosphorylase pyrophosphatase; pyrophosphate; transplantation; vascular calcification

Indexed keywords

AUTOTAXIN; CALCIUM; PYROPHOSPHATE; DIPHOSPHORIC ACID; ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1; INORGANIC PYROPHOSPHATASE; PHOSPHATE INTAKE; PHOSPHODIESTERASE; PYROPHOSPHORIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA DISEASE; AORTA GRAFT; ARTERY CALCIFICATION; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; ENZYME DEFICIENCY; EXTRACELLULAR SPACE; FEMALE; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PHOSPHATE INTAKE; PHOSPHATE METABOLISM; PRIORITY JOURNAL; TISSUE LEVEL; WILD TYPE; ADVERSE EFFECTS; ANIMAL; AORTA; AORTIC DISEASES; BLOOD; C57BL MOUSE; DEFICIENCY; DISEASE COURSE; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; TIME FACTOR; TRANSPLANTATION; VASCULAR CALCIFICATION;

ANIMALS; AORTA; AORTIC DISEASES; CALCIUM; DIPHOSPHATES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHORIC DIESTER HYDROLASES; PHOSPHORUS, DIETARY; PYROPHOSPHATASES; TIME FACTORS; VASCULAR CALCIFICATION;

EID: 84901924453     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.521     Document Type: Article

References (23)

1. Russell RGG, Bisaz S, Donath A et al. Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone. J Clin Invest 1971; 50: 961-969.
2. Lomashvili KA, Khawandi W, O'Neill WC. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 2005; 16: 2495-2500.
3. O'Neill WC, Sigrist MK, McIntyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant 2010; 25: 187-191.
4. O'Neill WC, Lomashvili KA, Malluche HH et al. Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int 2011; 79: 512-517.
5. Riser BL, Barreto FC, Rezg R et al. Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia. Nephrol Dial Transplant 2011; 26: 3349-3357.
6. Hessle L, Johnsson KA, Anderson HC et al. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci USA 2002; 99: 9445-9449.
7. Villa-Bellosta R, Wang X, Millan JL et al. Extracellular pyrophosphate metabolism and calcification in vascular smooth muscle. Am J Physiol Heart Circ Physiol 2011; 301: H61-H68.
8. Rutsch F, Vaingankar S, Johnson K et al. PC-1 nucleotide triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol 2001; 158: 543-554.
9. Murshed M, Harmey D, Millan JL et al. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 2005; 19: 1093-1104.
10. Gurley KA, Reimer RJ, Kingsley DM. Biochemical and genetic analysis of ANK in arthritis and bone disease. Am J Hum Genet 2006; 79: 1017-1029.
11. Harmey D, Hessle L, Narisawa S et al. Concerted regulation of inorganic pyrophosphate and osteopontin by Akp2, Enpp1 and Ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 2004; 164: 1199-1209.
12. MacKenzie NCW, Zhu D, Milne EM et al. Altered bone development and an increase in FGF-23 expression in Enpp12/2 mice. PLoS One 2012; 7: e32177.
13. van der Sluis IM, Boot AM, Vernooij M et al. Idiopathic infantile arterial calcification: clinical presentation, therapy and long-term follow-up. Eur J Pediatr 2006; 165: 590-593.
14. Costello JC, Rosenthal AK, Kurup IV et al. Parallel regulation of extracellular ATP and inorganic pyrophosphate: roles of growth factors, transduction modulators, and ANK. Connect Tissue Res 2010; 52: 139-146.
15. Fleisch H, Russell GG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 1966; 212: 901-903.
16. Meyer JL. Can biological calcification occur in the presence of pyrophosphate? Arch Biochem Biophys 1984; 231: 1-8.
17. Lomashvili KA, Garg P, Narisawa S et al. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int 2008; 73: 1024-1030.
18. Stefan C, Jansen S, Bollen M. Modulation of purinergic signaling by NPP-type ectophosphodiesterases. Purinergic Signal 2006; 2: 361-370.
19. St Hilaire C, Ziegler SG, Markello T et al. NT5E mutations and arterial calcifications. N Eng J Med 2011; 364: 432-442.
20. Goldfine ID, Maddux BA, Youngren JF et al. The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities. Endocr Rev 2008; 29: 62-75.
21. Schibler D, Russell GG, Fleisch H. Inhibition by pyrophosphate and polyphosphate of aortic calcification induced by vitamin D3 in rats. Clin Sci 1968; 35: 363-372.
22. Narisawa S, Harmey D, Yadav MC et al. Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification. J Bone Miner Res 2007; 22: 1700-1710.
23. Lomashvili KA, Monier-Faugere M-C, Wang X et al. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 2009; 75: 617-625.